Do It Now - Not Later: Lipid Management that Reduces Major CV Risks

Program Overview

Early and aggressive lowering of low-density lipoprotein cholesterol (LDL-C) reduces the risk of atherosclerotic cardiovascular disease (ASCVD) events in patients with hypercholesterolemia, and every 1.0 mmol/L reduction in LDL-C is estimated to lead to ~20% reduction in the relative risk of major cardiovascular events. Statins are the mainstay of hypercholesterolemia management, but many patients do not tolerate statin‐based treatment, which ultimately leads to medication nonadherence, ASCVD events, and higher healthcare costs. On the other hand, some patients, including those with pre-existing ASCVD or severe hypercholesterolemia, do not reach recommended LDL-C treatment targets despite intensive statin therapy. Non-statin agents can be useful for patients who inadequately respond to or are intolerant of statin therapy. Available non-statin therapies include ezetimibe, niacin, fibrates, proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, bile acid sequestrants, icosapent ethyl, and more recently, bempedoic acid and inclisiran. In this case-based activity, you will evaluate clinical encounters with patients who have high ASCVD risk, then suggest ways to improve these patients’ care. An expert in lipidology will then discuss strategies to optimize the care of patients who require additional LDL-C lowering.

Provided By
Association of Black Cardiologists, Inc.

Association of Black Cardiologists Accreditation Statement
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Association of Black Cardiologists Credit Designation Statement
Association of Black Cardiologists, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Provided By
National Association for Continuing Education

NACE AANP Approval

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.5 contact hours including 0.5 Pharmacology Hours.

How to claim credit

1.       Review the curriculum front matter.

2.       Participate in the curriculum.

3.       Complete the post-test and activity evaluation.

4.       You must score 70% or higher on the post-test to receive credit for this activity.

Policy on Faculty and Provider Disclosure

Accredited education provided by the National Association for Continuing Education (NACE) must demonstrate balance, independence, objectivity, and scientific rigor. All individuals in a position to influence content of NACE accredited education are required to disclose all financial relationships with ineligible companies within the previous 24-month period, regardless of relevance to the education. All relevant financial relationships and potential conflicts of interest will be mitigated prior to the activity.

NACE defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty and Planning Committee Disclosures

James A. Underberg has disclosed the following financial relationships:

• Consultant: Ambry, Amgen
• Advisor: Amarin, Amgen, Amryt Pharm, Esperion, Novartis, Regeneron
• Speaker: Amarin, Amgen, Amryt Pharm, Alexion Pharmaceuticals, Esperion, Regeneron
• Contracted Research: Amryt Pharm
• Speakers Bureau: Novartis

Pam Taub has disclosed the following financial relationships:

• Consultant: Amgen, Amarin, Bayer, Boehringer-Ingelheim, Esperion Therapeutics, Medtronic, Novartis, Novo-Nordisk
• Contracted Research: Applied Therapeutics
• Ownership Interest: Epirium Bio

All relevant financial relationships and potential conflicts of interest have been mitigated.

Faculty, and planners for this educational activity below not listed in the Faculty and Planning Committee Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Tierra Dillenburg, Association of Black Cardiologists, Inc., Activity Planning Committee.

Simon Schrick-Senasac, DO, MS, National Association for Continuing Education, Activity Planning Committee.

Gregg Sherman, MD, National Association for Continuing Education, Activity Planning Committee.

Michelle Frisch, MPH, National Association for Continuing Education, Activity Planning Committee.

Sheila Lucas, CWEP, National Association for Continuing Education, Activity Planning Committee.

Joshua Kilbridge, Kilbridge Associates, Medical Writer.

Angela Golden, DNP, FNP-C, FAANP, Family Nurse Practitioner has disclosed the following financial relationships:

• Consultant: Gelesis, Novo Nordisk, Unjury Nutrition
• Advisor: Acella Pharmaceutical, Currax Pharmaceuticals, Gelesis, Hisamitsu Pharmaceutical, Novo Nordisk, Salix Pharmaceutical, Unjury Nutrition
• Speaker: Acella Pharmaceutical, Currax Pharmaceutical, Novo Nordisk
• Receipt of Royalty: Springer

Disclosure of Commercial Support

This activity is supported by educational funding provided by Amgen; and an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled/Investigational Uses of Products

The content of the presentations may include discussion of unapproved or investigational uses of product or devices.

Course format/medium: Internet Enduring Activity

Estimated time to complete the activity: 30 minutes

COURSE VIEWING REQUIREMENTS